BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange ...
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...
PureTech Health plc ("PureTech" or the "Company"),a science-driven healthcare company seeking to solve some of the toughest health challenges in disruptive ways, today announces the successful pricing ...
Roche has struck a deal with PureTech Health to develop oral antisense oligonucleotides. The pact gives Roche access to PureTech’s milk-derived exosome technology in return for up to $36 million (€31 ...
PureTech Health(NASDAQ:PRTC) reported its second quarter 2025 earnings on Aug. 28, 2025, highlighting a cash balance of just under $320 million at the end of the first half of 2025, a reduction in ...
PureTech Health (LSE:PRTC) announced that its founded entity, Seaport Therapeutics, has set the terms for an upsized Nasdaq ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Daphne Zohar, who founded Boston ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results